Vir Biotechnology (VIR) Non-Current Assets (2018 - 2026)
Vir Biotechnology (VIR) posted Non-Current Assets of $502.6 million for Q1 2026, up 2.84% sequentially from $488.7 million in Q4 2025, and up 33.84% YoY from $375.5 million in Q1 2025.
Vir Biotechnology (VIR) Non-Current Assets (2018 - 2026) Analysis & Trends
Vir Biotechnology has reported Non-Current Assets for 9 years, with the latest figure at $502.6 million in Q1 2026.
- Quarterly Non-Current Assets rose 33.84% year-over-year to $502.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.9 billion (up 16.7% YoY) and the FY2025 annual result came in at $488.7 million, up 37.15% from the prior year.
- Non-Current Assets advanced to $502.6 million in Q1 2026 per VIR's latest filing, from $488.7 million in the prior quarter.
- Over five years, Non-Current Assets peaked at $580.9 million in Q1 2024 and troughed at $275.7 million in Q3 2023.
- A 5-year average of $386.9 million and a median of $356.4 million in 2024 frame the typical range for Non-Current Assets.
- The sharpest annual moves came in 2022 and 2025: Non-Current Assets surged 124.31% in 2022, then sank 35.35% in 2025.
- Over 5 years, Non-Current Assets stood at $283.0 million in 2022, then gained by 16.9% to $330.8 million in 2023, then increased by 7.71% to $356.4 million in 2024, then surged by 37.15% to $488.7 million in 2025, then gained by 2.84% to $502.6 million in 2026.
- According to Business Quant data, Non-Current Assets over the past three periods registered $502.6 million, $488.7 million, and $473.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | Vir Biotechnology | 1.56 Bn | 1.56 Bn | 238.95 Mn | 641.07 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 641.07 Mn |
| Mar 31, 2026 | 502.60 Mn |
| Dec 31, 2025 | 488.74 Mn |
| Sep 30, 2025 | 473.77 Mn |
| Jun 30, 2025 | 456.83 Mn |
| Mar 31, 2025 | 375.52 Mn |
| Dec 31, 2024 | 356.36 Mn |
| Sep 30, 2024 | 451.20 Mn |
| Jun 30, 2024 | 463.82 Mn |
| Mar 31, 2024 | 580.87 Mn |
| Dec 31, 2023 | 330.83 Mn |
| Sep 30, 2023 | 275.72 Mn |
| Jun 30, 2023 | 297.54 Mn |
| Mar 31, 2023 | 307.30 Mn |
| Dec 31, 2022 | 283.01 Mn |
| Sep 30, 2022 | 282.35 Mn |
| Jun 30, 2022 | 330.73 Mn |
| Mar 31, 2022 | 319.58 Mn |
| Dec 31, 2021 | 391.45 Mn |
| Sep 30, 2021 | 143.88 Mn |